We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Changes in Pituitary Iron and Volume With Deferasirox

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01376622
Recruitment Status : Completed
First Posted : June 20, 2011
Last Update Posted : June 20, 2011
Information provided by:

June 17, 2011
June 20, 2011
June 20, 2011
November 2008
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
Changes in Pituitary Iron and Volume With Deferasirox
Changes in Pituitary Iron and Volume With Deferasirox in Transfusional Iron Overload
Despite continuing advances in iron chelation therapy, iron toxicity of endocrine glands, particularly the pituitary gland, remains common in patients with transfusion dependent anemias. We would like to establish accurate population norms of pituitary R2 and volume and understand the progression of pituitary iron in transfused patients on Deferasirox.
Not Provided
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Transfusion Dependent Anemia
Iron Overload
Not Provided
  • Chronically Transfusion Patients
    Patients with transfusion dependent anemia (excluding sickle cell disease), ages 2-25, on Deferasirox chelation therapy, to be monitored over 2 years.
  • Controls
    Normal controls, ages 2-25, with no known brain abnormality or endocrine dysfunction.
Wood JC, Noetzl L, Hyderi A, Joukar M, Coates T, Mittelman S. Predicting pituitary iron and endocrine dysfunction. Ann N Y Acad Sci. 2010 Aug;1202:123-8. doi: 10.1111/j.1749-6632.2010.05545.x.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Not Provided
Not Provided

Inclusion Criteria:

  • Currently on chronic transfusion therapy.
  • Duration of chronic transfusion >1 year.
  • Age 2 to 25 years
  • On deferasirox monotherapy for the duration of the study.
  • Informed consent from legal guardian and/or patient.
  • On deferasirox for a minimum of 3 months at start of study.

Exclusion Criteria:

  • Sickle cell disease or sickle-beta zero genotype.
  • Combination of deferasirox and another iron chelator.
Sexes Eligible for Study: All
2 Years to 25 Years   (Child, Adult)
Contact information is only displayed when the study is recruiting subjects
United States
CCI-08-00143 ( Other Identifier: Committee on Clinical Investigations )
Not Provided
Not Provided
Dr. John Wood, Children's Hospital Los Angeles
Children's Hospital Los Angeles
Novartis Pharmaceuticals
Principal Investigator: John C Wood, MD, PhD Children's Hospital Los Angeles
Children's Hospital Los Angeles
July 2010